At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 47 enrolled
Drug / intervention
PF-04449913drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, ADMINISTERED AS SINGLE AGENT IN SELECT HEMATOLOGIC MALIGNANCIES
In Brief
A Phase 1 clinical trial evaluating PF-04449913 for Hematologic Malignancies. Completed, enrolled 47 participants across 6 sites in 2 countries.
Detailed Summary
This study examines the effect of a small molecule inhibitor to the Sonic Hedgehog pathway on select hematologic malignancies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematologic Malignancies
CountriesItaly, United States
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2009
Enrollment StartMar 2010
Primary CompletionSep 2012
Study CompletionFeb 2013
TodayJul 2026
First PostedAug 6, 2009
Enrollment StartMar 3, 2010
Primary CompletionSep 26, 2012
Study CompletionFeb 27, 2013
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 16.9 years ago
Interventions
PF-04449913drug
Escalating doses of PF-04449913 administered as tablets PO QD continuously in 28 day cycles